CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by progressive lung fibrosis, respiratory failure, and substantial mortality, particularly among older adults. While prior studies have described historical ILD mortality trends, comprehensive analyses incorporating future projections, detailed geographic disparities, and socioeconomic variation remain limited.

Material and methods:
We analyzed CDC WONDER underlying-cause-of-death data for US adults aged ≥ 65 years from 1999 to 2020. ILD deaths were identified using ICD-10 code J84, and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Joinpoint regression was used to identify turning points in mortality trends, autoregressive integrated moving average (ARIMA) modeling was used to project AAMRs through 2030, and Socio-demographic Index (SDI)-based correlation and frontier analyses were used to evaluate geographic and socioeconomic disparities in ILD mortality.

Results:
A total of 305,452 ILD deaths were recorded among US adults aged ≥ 65 years, with an overall AAMR of 33.45 per 100,000 population. Mortality increased significantly from 1999 to 2006 and then stabilized through 2020, with ARIMA models projecting continued stability through 2030. Significant disparities persisted, with mortality rates highest among males, American Indian or Alaska Native populations, Hispanic or Latino individuals, and residents of Western and Midwestern states. State-level analyses showed that lower SDI was generally associated with higher AAMR, with several states exhibiting excess mortality relative to their socioeconomic development levels.

Conclusions:
Although ILD mortality among older US adults stabilized after the mid-2000s and is projected to remain stable through 2030, substantial disparities persist across sex, race/ethnicity, geography, and socioeconomic context. These findings suggest that future reductions in ILD mortality may depend less on broad population-level declines and more on targeted strategies focused on high-burden groups and regions.
REFERENCES (25)
1.
Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet 2022; 400: 769-86.
 
2.
Guler SA, Corte TJ. Interstitial lung disease in 2020: a history of progress. Clin Chest Med 2021; 42: 229-39.
 
3.
Ochman M, Urlik M, Tatoj Z, et al. Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis - single-centre experience. Arch Med Sci 2020; 16: 621-6.
 
4.
Leary C, Bine C, Baral N, et al. Trends in interstitial lung disease and the COVID-19 pandemic in the United States from 1999 to 2022. Respir Res 2025; 26: 277.
 
5.
Zeng Q, Jiang D. Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the Global Burden of Disease study 2019, and projections until 2030. Front Med 2023; 10: 1141372.
 
6.
Patterson KC, Shah RJ, Porteous MK, et al. Interstitial lung disease in the elderly. Chest 2017; 151: 838-44.
 
7.
Meyer KC. Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 3-17.
 
8.
Tikellis G, Holland AE. Health disparities and associated social determinants of health in interstitial lung disease: a narrative review. Eur Respir Rev 2025; 34: 240176.
 
9.
Goobie GC, Ryerson CJ, Johannson KA, et al. Neighborhood-level disadvantage impacts on patients with fibrotic interstitial lung disease. Am J Respir Crit Care Med 2022; 205: 459-67.
 
10.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.
 
11.
Kim HJ, Chen HS, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact. Stat Med 2022; 41: 3102-30.
 
12.
Newbold P. ARIMA model building and the time series analysis approach to forecasting. J Forecast. 1983; 2: 23–35.
 
13.
Jian Y, Zhu D, Zhou D, et al. ARIMA model for predicting chronic kidney disease and estimating its economic burden in China. BMC Public Health 2022; 22: 2456.
 
14.
Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018; 6: 138-53.
 
15.
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018; 378: 1811-23.
 
16.
Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26: 170057.
 
17.
Lamb YN. Nintedanib: a review in fibrotic interstitial lung diseases. Drugs 2021; 81: 575-86.
 
18.
Yüksel A, Nezalzova P, Ulubay G. Efficacy of antifibrotics in slowing FVC and DLCO decline in progressive pulmonary fibrosis: a real world experience. Arch Med Sci 2025. DOI: https://doi.org/10.5114/aoms/2....
 
19.
Serrano Gotarredona MP, Navarro Herrero S, Gómez Izquierdo L, Rodríguez Portal JA. Smoking-related interstitial lung disease. Radiologia 2022; 64 Suppl 3: 277-89.
 
20.
Bellou V, Belbasis L, Evangelou E. Tobacco smoking and risk for pulmonary fibrosis: a prospective cohort study from the UK Biobank. Chest 2021; 160: 983-93.
 
21.
Pandit P, Perez RL, Roman J. Sex-based differences in interstitial lung disease. Am J Med Sci 2020; 360: 467-73.
 
22.
Adegunsoye A, Oldham JM, Bellam SK, et al. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. Eur Respir J 2018; 51: 1800255.
 
23.
Swigris JJ, Olson AL, Huie TJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med 2012; 106: 588-93.
 
24.
Adegunsoye A, Freiheit E, White EN, et al. Evaluation of pulmonary fibrosis outcomes by race and ethnicity in US adults. JAMA Netw Open 2023; 6: e232427.
 
25.
Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J 2016; 47: 1535-58.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top